Taysha Gene Therapies Total Current Liabilities 2020-2024 | TSHA
Taysha Gene Therapies total current liabilities from 2020 to 2024. Total current liabilities can be defined as the sum of all liabilities classified as current for having maturities of less than one year.
Taysha Gene Therapies Annual Total Current Liabilities
(Millions of US $) |
| 2023 |
$37 |
| 2022 |
$63 |
| 2021 |
$52 |
| 2020 |
$7 |
| 2019 |
$0 |
Taysha Gene Therapies Quarterly Total Current Liabilities
(Millions of US $) |
| 2024-06-30 |
$34 |
| 2024-03-31 |
$39 |
| 2023-12-31 |
$37 |
| 2023-09-30 |
$180 |
| 2023-06-30 |
$51 |
| 2023-03-31 |
$54 |
| 2022-12-31 |
$63 |
| 2022-09-30 |
$33 |
| 2022-06-30 |
$43 |
| 2022-03-31 |
$49 |
| 2021-12-31 |
$52 |
| 2021-09-30 |
$43 |
| 2021-06-30 |
$28 |
| 2021-03-31 |
$19 |
| 2020-12-31 |
$7 |
| 2020-09-30 |
$12 |
| 2020-06-30 |
|
| 2020-03-31 |
|
| 2019-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.334B |
$0.015B |
|
Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.
|
